Cutler Group’s NextCure NXTC Stock Holding History

Cutler Group’s Portfolio NXTC Stock Details NXTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-150	Closed	-$29K	–	5086
2020 Q2	$29K	Hold	150	–	–	﹤0.01%	2123
2020 Q1	$16K	Buy	150 +92	+159%	+$49.1K	﹤0.01%	2451
2019 Q4	$3K	Buy	+58	New	+$29.1K	﹤0.01%	3305

Other funds holding NXTC

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Cutler Group's NXTC Position: Q3 2023 in Review

Cutler Group sold out of NextCure (NXTC) in Q3 2023, closing a stake of 58 shares — an estimated $1K sold.

Cutler Group first reported a position in NXTC in Q4 2019 and held it in 14 quarters. The position peaked at $78K in Q4 2019. 39 funds tracked by Wall St. Rank hold NXTC as of Q3 2023.

Cutler Group reported no remaining NextCure position as of Q3 2023 after selling out during the quarter.
Cutler Group sold 58 NextCure shares in Q3 2023, an estimated $1K.
Cutler Group first reported a position in NextCure in Q4 2019 and held it in 14 quarters.
Cutler Group's NextCure position peaked at $78K in Q4 2019.
39 funds tracked by Wall St. Rank held NextCure as of Q3 2023.

Based on Cutler Group's 13F filing for Q3 2023, filed 7 Nov 2023.